Home
>
US Stocks
>
Tcr2 Therapeutics Inc
Tcr2 Therapeutics Inc
TCRR

Tcr2 Therapeutics Inc (TCRR)

$6.710.3%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$6.83
Today Low/High$6.68 / $6.89
52 Week Low/High$6.57 / $35.86
Market Cap$261.26M

Company Details

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
OrganisationTcr2 Therapeutics Inc
HeadquatersCambridge, Massachusetts, US
Employees118
IndustryPharmaceuticals: Major
CEOGarry Menzel

Discover more

Frequently Asked Questions

What is Tcr2 Therapeutics Inc (TCRR) share price today?

Can Indians buy Tcr2 Therapeutics Inc (TCRR) shares?

How can I buy Tcr2 Therapeutics Inc (TCRR) shares from India?

Can Fractional shares of Tcr2 Therapeutics Inc (TCRR) be purchased?

What are the documents required to start investing in Tcr2 Therapeutics Inc (TCRR) stocks?

We are a SEBI registered investement advisor